ストックスクリーナーアプリを入手
3.18
5.92%
-0.20
アフターアワーズ：
3.25
0.07
+2.20%
前日終値:
$3.38
開ける：
$3.32
24時間の取引高:
932.43K
Relative Volume:
1.52
時価総額：
$210.80M
収益：
-
当期純損益:
$-27.03M
株価収益率:
-5.6786
EPS:
-0.56
ネットキャッシュフロー:
$-23.97M
1週間 パフォーマンス:
-25.18%
1か月 パフォーマンス:
-21.29%
6か月 パフォーマンス:
-39.77%
1年 パフォーマンス:
+78.65%
1日の値動き範囲:
$3.08
$3.43
1週間の範囲:
$3.08
$4.3848
52週間の値動き範囲:
$1.30
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
名前
Corvus Pharmaceuticals Inc
セクター
電話
(650) 900-4520
住所
863 MITTEN ROAD, BURLINGAME, CA
CRVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
3.18 | 210.80M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-02 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-18 | 開始されました | Oppenheimer | Outperform |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-05-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-10 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-05-29 | 開始されました | ROTH Capital | Buy |
| 2017-08-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 開始されました | Credit Suisse | Outperform |
| 2016-04-18 | 開始されました | Guggenheim | Buy |
すべてを表示
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha
Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada
Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st
Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable
Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener
Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - Greenwich Time
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India
Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter
Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times
New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients - Stock Titan
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - The Manila Times
Corvus Pharmaceuticals to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
Corvus Pharmaceuticals Reveals Q4 Earnings Date: Complete Financial Picture Coming March 25 - StockTitan
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) - The Manila Times
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for ... - The Bakersfield Californian
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with - EIN News
Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts - Armenian Reporter
Insiders Enjoy US$1.7m Return After Buying Corvus Pharmaceuticals Stock - Simply Wall St
Adicet Bio (NASDAQ:ACET) versus Corvus Pharmaceuticals (NASDAQ:CRVS) Head to Head Analysis - Defense World
When (CRVS) Moves Investors should Listen - Stock Traders Daily
Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Exclusive Healthcare Insights: Corvus Pharma Takes Center Stage at Major Oppenheimer Conference - StockTitan
JPMorgan Chase & Co. Buys 40,404 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.38 Average Target Price from Analysts - Defense World
Analysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - MarketBeat
Cantor Fitzgerald Comments on CRVS FY2025 Earnings - Defense World
Equities Analysts Offer Predictions for CRVS FY2025 Earnings - MarketBeat
CRVS’s Stock Market Adventure: -8.04% YTD Growth Amidst Volatility - The InvestChronicle
Corvus Pharmaceuticals (NASDAQ: CRVS) Announces Positive Interim Data from Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisOn January 13, 2025, Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, released encouraging int - Defense World
Corvus Pharmaceuticals Inc (CRVS) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):